Angela Boyhan joins Norgine
This article was originally published in Scrip
Dr Angela Boyhan has joined the European speciality pharmaceutical company Norgineas director of evaluation and alliances. Dr Boyhan was most recently project and portfolio manager of the Oncology Commercial Centre of Excellence, where she was responsible for project management of oncology product launches in Europe and oncology portfolio management. She previously held roles as project manager and leader at GlaxoSmithKline, leading product development teams across different stages of development in neurology, infectious diseases and oncology.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.